Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

AURAAura Biosciences, Inc.

Nasdaq · CIK 0001501796
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity typeoperating
SIC2836 Biological Products, (No Diagnostic Substances)
FY end1231
XBRL facts219

Identity from submissions API

NameAura Biosciences, Inc.
CIK0001501796
TickersAURA
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SIC2836 Biological Products, (No Diagnostic Substances)
EIN320271970
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone(617)500-8864
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
80 GUEST STREET
BOSTON
MA
02135
MA
Mailing address
80 GUEST STREET
BOSTON
MA
02135
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

388 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-128723 005-92997 261563792 34 14456
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-464008 005-92997 261563314 34 21060
2026-11-16 4 xslF345X06/form4-11162026_101156.xml 0001997710-26-000008 5585
2026-11-16 144 xsl144X01/primary_doc.xml 0001997710-26-000007 001-40971 261562919 33 11696
2026-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-007763 005-92997 261552260 34 18199
2026-11-09 10-Q 10-Q 0001193125-26-452636 001-40971 261533796 34 11007225 1 1
2026-11-09 8-K 8-K 2.02,8.01,9.01 0001193125-26-452620 001-40971 261533774 34 10017096 1 1
2026-10-27 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-003757 005-92997 261491584 34 10798
2026-10-01 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001470831-26-000917 005-92997 261431360 34 153229
2026-09-01 4 xslF345X06/form4-09012026_090914.xml 0001946505-26-000009 14949
2026-09-01 4 xslF345X06/form4-09012026_090933.xml 0002148785-26-000009 14973
2026-09-01 4 xslF345X06/form4-09012026_090929.xml 0001997710-26-000004 14976
2026-09-01 4 xslF345X06/form4-09012026_090904.xml 0002042910-26-000003 14938
2026-09-01 4 xslF345X06/form4-09012026_090941.xml 0002148701-26-000008 14965
2026-09-01 S-8 S-8 0001193125-26-378494 333-298689 261351289 33 587256 1 1
2026-08-20 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-002723 333-298228 261301600 33 1714
2026-08-18 CORRESP filename1.htm 0001193125-26-355417 9310
2026-08-17 UPLOAD filename1.pdf 0000000000-26-008094 333-298228 146690
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001231919-26-000913 005-92997 261282424 34 34409
2026-08-14 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001019056-26-000129 005-92997 261275822 34 10426
2026-08-12 3 xslF345X06/form3-08122026_080802.xml 0001946505-26-000006 9611
2026-08-12 3 xslF345X06/form3-08122026_080822.xml 0002148785-26-000005 9754
2026-08-12 3 xslF345X06/form3-08122026_080859.xml 0002148701-26-000005 9755
2026-08-12 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-004960 005-92997 261266215 34 12939
2026-08-11 S-3 S-3 0001193125-26-344699 333-298228 261263453 33 930215 1 1
2026-08-11 10-Q 10-Q 0001193125-26-343429 001-40971 261260608 34 10922278 1 1
2026-08-11 8-K 8-K 2.02,2.05,5.02,8.01,9.01 0001193125-26-343408 001-40971 261260584 34 10085318 1 1
2026-08-05 8-K 8-K 5.07 0001193125-26-335157 001-40971 261243742 34 181485 1 1
2026-07-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-002193 005-92997 261206108 34 10848
2026-07-08 4 4 0001193125-26-298542 7215
2026-07-08 3 3 0001193125-26-298538 15994
2026-07-08 8-K 8-K 5.02,9.01 0001193125-26-297992 001-40971 261160763 34 259548 1 1
2026-07-01 4 4 0001193125-26-292685 4981
2026-06-29 DEF 14A DEF 14A 0001193125-26-288498 001-40971 261137087 34 2905733 1 1
2026-06-17 PRE 14A PRE 14A 0001193125-26-274232 001-40971 261098946 34 2922073 1 1
2026-06-16 144 xsl144X01/primary_doc.xml 0001193125-26-272705 001-40971 261095076 33 4598
2026-06-16 4 4 0001193125-26-272703 4936
2026-06-15 4 4 0001193125-26-271171 7275
2026-06-15 4 4 0001193125-26-271170 7312
2026-06-15 4 4 0001193125-26-271168 10019
2026-06-15 4 4 0001193125-26-271165 7319
2026-06-11 8-K 8-K 5.07 0001193125-26-267676 001-40971 261083566 34 179657 1 1
2026-05-19 4 4 0001580111-26-000009 9633
2026-05-19 S-8 S-8 0001193125-26-230896 333-296029 26999373 33 302049 1 1
2026-05-12 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-219992 005-92997 26970206 34 129202
2026-05-11 4 OWNERSHIP DOCUMENT 0000950142-26-001346 7975
2026-05-11 10-Q 10-Q 0001193125-26-216808 001-40971 26963414 34 8848619 1 1
2026-05-11 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0000950142-26-001345 005-92997 26963386 34 9510
2026-05-11 8-K 8-K 2.02,8.01,9.01 0001193125-26-216743 001-40971 26963137 34 24736996 1 1
2026-05-07 3 3 0001580111-26-000004 16097
2026-05-05 8-K 8-K 1.01,9.01 0001193125-26-206804 001-40971 26944698 34 707201 1 1
2026-05-05 424B5 424B5 0001193125-26-204513 333-278253 26939607 33 1524050
2026-05-04 8-K 8-K 1.01,2.02,8.01 0001193125-26-204049 001-40971 26937939 34 151238 1 1
2026-05-04 DEFA14A DEFA14A 0001193125-26-202638 001-40971 26934709 34 74284
2026-05-04 S-3MEF S-3MEF 0001193125-26-202563 333-295515 26934648 33 281058 1 1
2026-05-04 424B5 424B5 0001193125-26-202458 333-278253 26934568 33 1526849
2026-05-04 8-K 8-K 5.02,7.01,8.01,9.01 0001193125-26-202414 001-40971 26934542 34 203534 1 1
2026-04-20 ARS ARS 0001193125-26-164048 001-40971 26875286 34 3301964
2026-04-20 DEFA14A DEFA14A 0001193125-26-164016 001-40971 26875207 34 309206
2026-04-20 DEF 14A DEF 14A 0001193125-26-163933 001-40971 26875044 34 2978144 1 1
2026-04-16 144 xsl144X01/primary_doc.xml 0001193125-26-159580 001-40971 26868904 33 5152
2026-04-16 4 4 0001193125-26-159579 5384
2026-03-30 S-8 S-8 0001193125-26-130408 333-294724 26809974 33 379328 1 1
2026-03-30 10-K 10-K 0001193125-26-130401 001-40971 26809957 34 30599008 1 1
2026-03-30 8-K 8-K 2.02,8.01,9.01 0001193125-26-130383 001-40971 26809939 34 24699067 1 1
2026-03-03 4 4 0001193125-26-088170 7196
2026-03-03 4 4 0001193125-26-088168 7268
2026-03-03 4 4 0001193125-26-088162 8185
2026-03-03 4 4 0001193125-26-088158 7221
2026-03-03 4 4 0001193125-26-088154 7207
2026-03-03 4 4 0001193125-26-088150 7183
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001062993-26-001017 005-92997 26644905 34 19424
2026-02-17 144 xsl144X01/primary_doc.xml 0001193125-26-055509 001-40971 26644714 33 4550
2026-02-17 144 xsl144X01/primary_doc.xml 0001193125-26-055508 001-40971 26644707 33 5201
2026-02-17 144 xsl144X01/primary_doc.xml 0001193125-26-055507 001-40971 26644706 33 5799
2026-02-17 144 xsl144X01/primary_doc.xml 0001193125-26-055504 001-40971 26644701 33 5759
2026-02-17 144 xsl144X01/primary_doc.xml 0001193125-26-055502 001-40971 26644697 33 5867
2026-02-17 4 4 0001193125-26-055499 5247
2026-02-17 4 4 0001193125-26-055497 5271
2026-02-17 4 4 0001193125-26-055496 5257
2026-02-17 4 4 0001193125-26-055494 5234
2026-02-17 4 4 0001193125-26-055487 6234
2026-02-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001231919-26-000155 005-92997 26634873 34 47145
2026-01-20 144 xsl144X01/primary_doc.xml 0001193125-26-016944 001-40971 26544263 33 5154
2026-01-20 144 xsl144X01/primary_doc.xml 0001193125-26-016941 001-40971 26544259 33 5262
2026-01-20 4 4 0001193125-26-016939 4713
2026-01-20 4 4 0001193125-26-016938 6234
2025-11-17 144 xsl144X01/primary_doc.xml 0001193125-25-284880 001-40971 251492278 33 4589
2025-11-17 4 4 0001193125-25-284878 5258
2025-11-13 10-Q 10-Q 0001193125-25-278817 001-40971 251475379 34 9860375 1 1
2025-11-13 8-K 8-K 2.02,8.01,9.01 0001193125-25-278810 001-40971 251475357 34 22827386 1 1
2025-10-29 144 xsl144X01/primary_doc.xml 0001193125-25-256625 001-40971 251430897 33 5156
2025-10-29 144 xsl144X01/primary_doc.xml 0001193125-25-256622 001-40971 251430894 33 4652
2025-10-29 4 4 0001193125-25-256620 4713
2025-10-29 4 4 0001193125-25-256619 5713
2025-10-17 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-25-002503 005-92997 251401766 34 10707
2025-10-16 144 xsl144X01/primary_doc.xml 0001193125-25-241623 001-40971 251398523 33 4600
2025-10-16 4 4 0001193125-25-241622 4751
2025-08-18 4 4 0000950170-25-109767 29131
2025-08-18 144 xsl144X01/primary_doc.xml 0001950047-25-005973 001-40971 251228162 33 4606
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-021797 005-92997 251217153 34 48941
2025-08-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000919574-25-004722 005-92997 251213704 34 18567
2025-08-13 10-Q 10-Q 0001193125-25-179426 001-40971 251208979 34 9703748 1 1
2025-08-13 8-K 8-K 2.02,8.01,9.01 0001193125-25-179418 001-40971 251208959 34 26052339 1 1
2025-07-16 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-002483 005-92997 251128439 34 10759
2025-06-18 4 4 0000950170-25-087891 20201
2025-06-18 4 4 0000950170-25-087890 9882
2025-06-18 4 4 0000950170-25-087889 20199
2025-06-18 8-K 8-K 5.07 0000950170-25-087885 001-40971 251056928 34 179890 1 1
2025-06-04 4 4 0000950170-25-081616 7264
2025-06-04 4 4 0000950170-25-081615 9409
2025-05-23 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-014432 005-92997 25982218 34 82257
2025-05-20 4 4 0000950170-25-075412 24152
2025-05-20 4 4 0000950170-25-075403 8575
2025-05-19 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000902664-25-002479 005-92997 25964542 34 9440
2025-05-16 144 xsl144X01/primary_doc.xml 0000950170-25-073664 001-40971 25960198 33 4593
2025-05-16 3 3 0000950170-25-073661 17934
2025-05-16 8-K 8-K 1.01,8.01,9.01 0001193125-25-121677 001-40971 25959081 34 22886498 1 1
2025-05-16 424B5 424B5 0001193125-25-121280 333-278253 25956917 33 816880
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001344676-25-000018 005-92997 25950172 34 10067
2025-05-15 424B5 424B5 0001193125-25-120252 333-278253 25948524 33 818943
2025-05-15 10-Q 10-Q 0000950170-25-071907 001-40971 25948359 34 8368392 1 1
2025-05-15 8-K 8-K 2.02,5.02,9.01 0000950170-25-071839 001-40971 25948338 34 428966 1 1
2025-05-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001580642-25-003115 005-92997 25944880 34 11081
2025-05-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001580642-25-003100 005-92997 25941554 34 11113
2025-04-24 ARS ARS 0000950170-25-058076 001-40971 25867593 34 2995715
2025-04-24 DEFA14A DEFA14A 0000950170-25-058070 001-40971 25867568 34 295015
2025-04-24 DEF 14A DEF 14A 0000950170-25-058062 001-40971 25867511 34 2982478 1 1
2025-04-16 144 xsl144X01/primary_doc.xml 0000950170-25-054957 001-40971 25843994 33 5752
2025-04-16 144 xsl144X01/primary_doc.xml 0000950170-25-054956 001-40971 25843993 33 4548
2025-04-16 4 4 0000950170-25-054954 5253
2025-04-16 4 4 0000950170-25-054953 17388
2025-04-11 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000919574-25-002448 005-92997 25833804 34 17175
2025-04-02 4 4 0000950170-25-049279 7059
2025-04-02 3 3 0000950170-25-049273 15091
2025-04-02 8-K 8-K 5.02,9.01 0000950170-25-048880 001-40971 25802130 34 206686 1 1
2025-03-24 S-8 S-8 0000950170-25-043965 333-286061 25765075 33 182434
2025-03-24 10-K 10-K 0000950170-25-043943 001-40971 25764941 34 35278468 1 1
2025-03-24 8-K 8-K 2.02,8.01,9.01 0000950170-25-043809 001-40971 25764078 34 28572917 1 1
2025-02-18 144 xsl144X01/primary_doc.xml 0000950170-25-022660 001-40971 25636800 33 4604
2025-02-18 144 xsl144X01/primary_doc.xml 0000950170-25-022659 001-40971 25636799 33 5202
2025-02-18 144 xsl144X01/primary_doc.xml 0000950170-25-022657 001-40971 25636797 33 5159
2025-02-18 144 xsl144X01/primary_doc.xml 0000950170-25-022656 001-40971 25636796 33 5272
2025-02-18 4 4 0000950170-25-022655 4756
2025-02-18 4 4 0000950170-25-022654 4740
2025-02-18 4 4 0000950170-25-022653 4742
2025-02-18 4 4 0000950170-25-022651 6243
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001580642-25-001009 005-92997 25625325 34 14004
2025-02-04 4 4 0000950170-25-013830 8734
2025-02-04 4 4 0000950170-25-013829 7226
2025-02-04 4 4 0000950170-25-013828 7213
2025-02-04 4 4 0000950170-25-013827 7197
2025-02-04 4 4 0000950170-25-013825 7210
2025-01-21 144 xsl144X01/primary_doc.xml 0000950170-25-007497 001-40971 25543700 33 5270
2025-01-21 144 xsl144X01/primary_doc.xml 0000950170-25-007496 001-40971 25543699 33 5157
2025-01-21 4 4 0000950170-25-007495 6243
2025-01-21 4 4 0000950170-25-007494 5256
2025-01-03 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001019056-25-000007 005-92997 25508587 34 18773
2025-01-03 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001019056-25-000005 005-92997 25507591 34 18930
2024-11-18 4 4 0000950170-24-128206 21511
2024-11-18 144 xsl144X01/primary_doc.xml 0000950170-24-128172 001-40971 241472984 33 4527
2024-11-14 SC 13G/A SC 13G/A 0001104659-24-119334 005-92997 241464790 34 65815
2024-11-14 SC 13G/A SC 13G/A 0001104659-24-118966 005-92997 241462681 34 136575
2024-11-12 10-Q 10-Q 0000950170-24-125428 001-40971 241448383 34 8691287 1 1
2024-11-12 8-K 8-K 2.02,8.01,9.01 0000950170-24-125390 001-40971 241448172 34 21304234 1 1
2024-11-12 SC 13G/A p24-3041sc13ga.htm 0000902664-24-006403 005-92997 241444210 34 71272
2024-11-08 SC 13G us05153u1079_110824.txt 0002012383-24-003494 005-92997 241439622 34 13589
2024-10-29 144 xsl144X01/primary_doc.xml 0000950170-24-118485 001-40971 241407129 33 4556
2024-10-29 144 xsl144X01/primary_doc.xml 0000950170-24-118482 001-40971 241407125 33 5287
2024-10-29 144 xsl144X01/primary_doc.xml 0000950170-24-118481 001-40971 241407124 33 5221
2024-10-29 4 4 0000950170-24-118478 6246
2024-10-29 4 4 0000950170-24-118475 5259
2024-10-29 3 3 0000950170-24-118473 31900
2024-10-22 SC 13G us05153u1079_102224.txt 0002012383-24-001608 005-92997 241387334 34 13577
2024-10-21 4 4 0000950170-24-116029 30519
2024-10-18 4 4 0000950170-24-115729 9680
2024-10-18 144 xsl144X01/primary_doc.xml 0001950047-24-007810 001-40971 241381000 33 4716
2024-10-18 144 xsl144X01/primary_doc.xml 0001950047-24-007809 001-40971 241380999 33 4810
2024-10-17 8-K 8-K 7.01,8.01,9.01 0001193125-24-238959 001-40971 241378322 34 18485368 1 1
2024-10-16 4 4 0000950170-24-115150 16881
2024-10-16 144 xsl144X01/primary_doc.xml 0000950170-24-115148 001-40971 241375736 33 4686
2024-10-01 4 4 0000950170-24-110933 22706
2024-09-27 8-K 8-K 5.02 0001193125-24-227950 001-40971 241334882 34 154447 1 1
2024-09-12 8-K 8-K 7.01,8.01,9.01 0001193125-24-217619 001-40971 241293859 34 14116189 1 1
2024-08-08 10-Q 10-Q 0000950170-24-093308 001-40971 241186010 34 8383691 1 1
2024-08-08 8-K 8-K 2.02,8.01,9.01 0000950170-24-093298 001-40971 241185972 34 17977849 1 1
2024-06-24 4 4 0000950170-24-076715 7191
2024-06-24 4 4 0000950170-24-076713 7184
2024-06-24 4 4 0000950170-24-076707 9891
2024-06-21 8-K 8-K 5.03,5.07,9.01 0001193125-24-165656 001-40971 241060208 34 174399 1 1
2024-06-14 DEFA14A DEFA14A 0001193125-24-161687 001-40971 241045518 34 158890
2024-06-14 10-K/A 10-K/A 0001193125-24-161680 001-40971 241045445 34 527942 1 1
2024-06-04 8-K 8-K 8.01,9.01 0001193125-24-154364 001-40971 241019228 34 12669173 1 1
2024-05-09 10-Q 10-Q 0000950170-24-056265 001-40971 24928531 34 7679448 1 1
2024-05-09 8-K 8-K 2.02,9.01 0000950170-24-056252 001-40971 24928498 34 344290 1 1
2024-04-25 ARS ARS 0001193125-24-113891 001-40971 24876334 34 3108181
2024-04-25 DEFA14A DEFA14A 0001193125-24-113884 001-40971 24876296 34 797761
2024-04-25 DEF 14A DEF 14A 0001193125-24-113878 001-40971 24876232 34 447226
2024-04-15 8-K 8-K 5.02 0001193125-24-096204 001-40971 24844717 34 144136 1 1
2024-04-15 PRE 14A PRE 14A 0001193125-24-096191 001-40971 24844679 34 448608
2024-04-05 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-04-05 16:05:00 9999999995-24-000875 333-278253 24827978 33 1720
2024-04-04 4 4 0000950170-24-041803 7180
2024-04-04 3 3 0000950170-24-041796 15374
2024-04-03 CORRESP filename1.htm 0001193125-24-086018 6117
2024-04-03 UPLOAD filename1.pdf 0000000000-24-003569 333-278253 40269
2024-03-27 S-3 S-3 0001193125-24-078268 333-278253 24785889 33 1092481
2024-03-27 S-8 S-8 0001193125-24-078257 333-278252 24785830 33 67187
2024-03-27 10-K 10-K 0000950170-24-036814 001-40971 24785757 34 19432728 1 1
2024-03-27 8-K 8-K 2.02,9.01 0000950170-24-036811 001-40971 24785750 34 351692 1 1
2024-03-25 3 3 0000950170-24-035901 18141
2024-03-04 144 xsl144X01/primary_doc.xml 0001950047-24-001794 001-40971 24716465 33 16453
2024-02-23 144 xsl144X01/primary_doc.xml 0001950047-24-001343 001-40971 24671542 33 14723
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-023933 005-92997 24639960 34 137998
2024-02-07 SC 13G/A AURA BIOSCIENCES, INC. 0000902664-24-001181 005-92997 24602209 34 95691
2024-02-02 4 4 0000950170-24-010461 7214
2024-02-02 4 4 0000950170-24-010462 7196
2024-02-02 4 4 0000950170-24-010460 8195
2024-01-24 4 4 0000950170-24-006988 6244
2024-01-24 4 4 0000950170-24-006987 5242
2024-01-24 144 xsl144X01/primary_doc.xml 0000950170-24-006963 001-40971 24556381 33 5887
2024-01-24 144 xsl144X01/primary_doc.xml 0000950170-24-006962 001-40971 24556382 33 6450
2024-01-08 144 xsl144X01/primary_doc.xml 0001950047-24-000190 001-40971 24520203 33 12034
2024-01-08 8-K 8-K 8.01,9.01 0001193125-24-003887 001-40971 24518341 34 5149863 1 1
2024-01-02 144 xsl144X01/primary_doc.xml 0001950047-24-000022 001-40971 24502853 33 11313
2023-12-15 144 xsl144X01/primary_doc.xml 0001950047-23-006144 001-40971 231490802 33 5367
2023-12-11 SC 13G/A SC 13G/A 0001580642-23-006643 005-92997 231478933 34 56209
2023-11-09 4 4 0000950170-23-062214 13917
2023-11-09 4 xslF345X05/ownership.xml 0000902664-23-005429 7581
2023-11-09 SC 13D/A AURA BIOSCIENCES, INC. 0000902664-23-005428 005-92997 231393174 34 85058
2023-11-09 10-Q 10-Q 0000950170-23-062097 001-40971 231392809 34 9610953 1 1
2023-11-09 8-K 8-K 1.01,2.02,9.01 0000950170-23-062074 001-40971 231392612 34 1017457 1 1
2023-11-07 4 4 0000950170-23-060499 9593
2023-11-07 4 4 0000950170-23-060493 8592
2023-11-07 424B5 424B5 0001193125-23-272529 333-268105 231384865 33 733315
2023-11-06 144 xsl144X01/primary_doc.xml 0001950047-23-004765 001-40971 231380271 33 5945
2023-11-06 144 xsl144X01/primary_doc.xml 0001950047-23-004757 001-40971 231380241 33 5317
2023-11-06 424B5 424B5 0001193125-23-271382 333-268105 231380186 33 736158
2023-11-06 8-K 8-K 7.01,8.01,9.01 0001193125-23-271351 001-40971 231379881 34 16551190 1 1
2023-11-03 4 4 0000950170-23-058900 7124
2023-11-03 144 xsl144X01/primary_doc.xml 0000950170-23-058843 001-40971 231376550 33 4684
2023-11-03 144 xsl144X01/primary_doc.xml 0000950170-23-058842 001-40971 231376507 33 4612
2023-11-03 144 xsl144X01/primary_doc.xml 0000950170-23-058841 001-40971 231376501 33 5086
2023-11-01 4 4 0000950170-23-057643 5289
2023-11-01 4 4 0000950170-23-057640 6287
2023-10-23 3 3 0000950170-23-054690 14671
2023-10-05 4 4 0000950170-23-052244 9065
2023-10-02 8-K 8-K 5.02,9.01 0001193125-23-249055 001-40971 231299756 34 195049 1 1
2023-08-09 10-Q 10-Q 0000950170-23-040138 001-40971 231153342 34 9765169 1 1
2023-08-09 8-K 8-K 2.02,8.01,9.01 0000950170-23-040136 001-40971 231153331 34 17357480 1 1
2023-06-09 4 FORM 4 SUBMISSION 0000899243-23-015209 5328
2023-06-09 4 FORM 4 SUBMISSION 0000899243-23-015206 5342
2023-06-09 4 FORM 4 SUBMISSION 0000899243-23-015205 5405
2023-06-09 4 FORM 4 SUBMISSION 0000899243-23-015203 5321
2023-06-07 144 xsl144X01/primary_doc.xml 0001972362-23-000319 001-40971 231000088 33 4650
2023-06-07 8-K 8-K 5.07 0001193125-23-162617 001-40971 23999622 34 149738 1 1
2023-06-02 144 xsl144X01/primary_doc.xml 0001972362-23-000287 001-40971 23990785 33 4052
2023-05-11 10-Q 10-Q 0000950170-23-021302 001-40971 23911471 34 9137970 1 1
2023-05-11 8-K 8-K 2.02,8.01,9.01 0000950170-23-021284 001-40971 23911373 34 21027831 1 1
2023-04-25 ARS ARS 0001193125-23-115308 001-40971 23844968 34 3716388
2023-04-25 DEFA14A DEFA14A 0001193125-23-115294 001-40971 23844912 34 336382
2023-04-25 DEF 14A DEF 14A 0001193125-23-115288 001-40971 23844874 34 689356
2023-04-04 8-K 8-K 5.02 0001193125-23-090316 001-40971 23795105 34 143595 1 1
2023-03-15 S-8 S-8 0001193125-23-071431 333-270571 23735866 33 65892
2023-03-15 10-K 10-K 0000950170-23-008166 001-40971 23735586 34 22873963 1 1
2023-03-15 8-K 8-K 2.02,9.01 0000950170-23-008163 001-40971 23735573 34 446806 1 1
2023-02-16 8-K 8-K 7.01,8.01,9.01 0001193125-23-040742 001-40971 23637203 34 17829016 1 1
2023-02-14 SC 13G SC 13G 0001580642-23-000861 005-92997 23626460 34 58467
2023-02-14 SC 13G/A SC 13G/A 0001104659-23-020726 005-92997 23622639 34 137991
2023-02-10 SC 13G/A SC 13G/A 0001193125-23-032710 005-92997 23612732 34 62155
2023-02-09 SC 13G/A AURA BIOSCIENCES, INC. 0000902664-23-001331 005-92997 23602216 34 103117
2023-01-23 4 FORM 4 SUBMISSION 0000899243-23-002437 7358
2023-01-23 4 FORM 4 SUBMISSION 0000899243-23-002436 7375
2023-01-23 4 FORM 4 SUBMISSION 0000899243-23-002434 8337
2023-01-23 4 FORM 4 SUBMISSION 0000899243-23-002433 7397
2023-01-20 SC 13G/A SC 13G/A 0001104659-23-005392 005-92997 23540946 34 86451
2023-01-09 4 FORM 4 SUBMISSION 0000899243-23-001324 10034
2023-01-06 8-K 8-K 8.01,9.01 0001193125-23-003670 001-40971 23516006 34 15404798 1 1
2022-12-30 4 FORM 4 SUBMISSION 0000899243-22-039594 6640
2022-12-15 4 FORM 4 SUBMISSION 0000899243-22-038695 6642
2022-12-15 SC 13G AURA BIOSCIENCES, INC. 0000902664-22-005182 005-92997 221465332 34 104933
2022-12-07 4 xslF345X03/ownership.xml 0000902664-22-005061 7562
2022-12-07 SC 13D/A AURA BIOSCIENCES, INC. 0000902664-22-005060 005-92997 221450485 34 51098
2022-12-05 8-K 8-K 1.01,9.01 0001193125-22-298535 001-40971 221445812 34 500030 1 1
2022-12-01 424B5 424B5 0001193125-22-296622 333-268105 221439414 33 789875
2022-11-30 424B5 424B5 0001193125-22-295399 333-268105 221435764 33 793526
2022-11-30 8-K 8-K 8.01,9.01 0001193125-22-295368 001-40971 221435594 34 17336003 1 1
2022-11-10 10-Q 10-Q 0000950170-22-024150 001-40971 221374906 34 10562242 1 1
2022-11-10 8-K 8-K 2.02,8.01,9.01 0000950170-22-024145 001-40971 221374885 34 537192 1 1
2022-11-07 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2022-11-07 16:00:00 9999999995-22-003223 333-268105 221367036 33 1672
2022-11-03 CORRESP filename1.htm 0001193125-22-276950 6304
2022-11-03 UPLOAD filename1.pdf 0000000000-22-011989 40146
2022-11-02 4 FORM 4 SUBMISSION 0000899243-22-034838 5348
2022-11-02 4 FORM 4 SUBMISSION 0000899243-22-034837 5386
2022-11-02 4 FORM 4 SUBMISSION 0000899243-22-034836 6322
2022-11-02 4 FORM 4 SUBMISSION 0000899243-22-034834 5365
2022-11-01 S-3 S-3 0001193125-22-275062 333-268105 221351487 33 1285950
2022-10-03 8-K 8-K 7.01,8.01,9.01 0001193125-22-256110 001-40971 221285919 34 23573029 1 1
2022-09-28 8-K 8-K 7.01,9.01 0001193125-22-252714 001-40971 221272856 34 174686 1 1
2022-08-11 10-Q 10-Q 0000950170-22-016911 001-40971 221156303 34 12905340 1 1
2022-08-11 8-K 8-K 2.02,9.01 0000950170-22-016905 001-40971 221156253 34 507079 1 1
2022-06-30 8-K 8-K 7.01,9.01 0001193125-22-185580 001-40971 221056521 34 173062 1 1
2022-06-22 8-K 8-K 7.01,9.01 0001193125-22-178857 001-40971 221032746 34 15562745 1 1
2022-06-17 4 FORM 4 SUBMISSION 0000899243-22-023131 5386
2022-06-17 4 FORM 4 SUBMISSION 0000899243-22-023128 8628
2022-06-17 4 FORM 4 SUBMISSION 0000899243-22-023127 5302
2022-06-17 4 FORM 4 SUBMISSION 0000899243-22-023125 5309
2022-06-15 8-K 8-K 5.07 0001193125-22-174863 001-40971 221018439 34 150980 1 1
2022-06-14 4 FORM 4 SUBMISSION 0000899243-22-022456 13118
2022-05-27 8-K 8-K 7.01,9.01 0001193125-22-161235 001-40971 22971831 34 177410 1 1
2022-05-18 8-K 8-K 1.01,2.03 0001193125-22-154031 001-40971 22939096 34 146252 1 1
2022-05-12 10-Q 10-Q 0000950170-22-009719 001-40971 22918421 34 8801517 1 1
2022-05-12 8-K 8-K 2.02,9.01 0000950170-22-009706 001-40971 22918298 34 419220 1 1
2022-04-28 DEFA14A DEFA14A 0001193125-22-127660 001-40971 22867002 34 414750
2022-04-28 DEF 14A DEF 14A 0001193125-22-127614 001-40971 22866829 34 738579
2022-03-23 S-8 S-8 0001193125-22-082858 333-263801 22763852 33 61290
2022-03-23 10-K 10-K 0000950170-22-004425 001-40971 22763511 34 11989177 1 1
2022-03-23 8-K 8-K 2.02,9.01 0000950170-22-004419 001-40971 22763447 34 395310 1 1
2022-02-14 SC 13G/A AURA BIOSCIENCES, INC. 0001104659-22-021314 005-92997 22624837 34 139792
2022-02-14 SC 13G FORM SC 13G 0001062993-22-003816 005-92997 22623290 34 65439
2022-02-10 SC 13G/A SC 13G/A 0001193125-22-034542 005-92997 22614551 34 65270
2022-01-26 SC 13G SC 13G 0001193125-22-018285 005-92997 22557909 34 66188
2021-11-24 10-Q 10-Q 0000950170-21-004908 001-40971 211447032 34 9539670 1 1
2021-11-24 8-K 8-K 2.02,9.01 0000950170-21-004906 001-40971 211446892 34 510575 1 1
2021-11-12 SC 13G SC 13G 0001104659-21-138116 005-92997 211404051 34 85957
2021-11-12 SC 13G SC 13G 0001104659-21-138044 005-92997 211403449 34 137449
2021-11-10 SC 13D SC 13D 0001193125-21-325850 005-92997 211396222 34 141736
2021-11-10 SC 13G SC 13G 0001193125-21-325763 005-92997 211396028 34 57885
2021-11-04 4 FORM 4 SUBMISSION 0000899243-21-043033 32137
2021-11-04 SC 13D AURA BIOSCIENCES, INC. 0000902664-21-004741 005-92997 211380922 34 69233
2021-11-04 4 xslF345X03/ownership.xml 0000902664-21-004738 11947
2021-11-02 4 FORM 4 SUBMISSION 0000899243-21-042362 10532
2021-11-02 4 FORM 4 SUBMISSION 0000899243-21-042361 7530
2021-11-02 8-K 8-K 5.03,9.01 0001193125-21-316929 001-40971 211371236 34 20432
2021-11-01 424B4 424B4 0001193125-21-314667 333-260156 211365550 33 8636737
2021-10-29 4 FORM 4 SUBMISSION 0000899243-21-042095 5241
2021-10-29 4 FORM 4 SUBMISSION 0000899243-21-042094 7411
2021-10-29 4 FORM 4 SUBMISSION 0000899243-21-042090 8347
2021-10-29 4 FORM 4 SUBMISSION 0000899243-21-042089 7387
2021-10-29 4 FORM 4 SUBMISSION 0000899243-21-042087 5227
2021-10-29 4 FORM 4 SUBMISSION 0000899243-21-042083 7394
2021-10-29 4 FORM 4 SUBMISSION 0000899243-21-042080 5304
2021-10-29 4 FORM 4 SUBMISSION 0000899243-21-042078 7413
2021-10-29 4 FORM 4 SUBMISSION 0000899243-21-042075 5220
2021-10-29 S-8 S-8 0001193125-21-313316 333-260589 211363233 33 318354
2021-10-28 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2021-10-28 16:00:00 9999999995-21-004081 333-260156 211360474 33 1680
2021-10-28 S-1MEF S-1MEF 0001193125-21-311860 333-260574 211360241 33 48736
2021-10-28 3 xslF345X02/ownership.xml 0000902664-21-004649 7364
2021-10-28 3 FORM 3 SUBMISSION 0000899243-21-041974 12304
2021-10-28 3 FORM 3 SUBMISSION 0000899243-21-041968 13408
2021-10-28 3 FORM 3 SUBMISSION 0000899243-21-041967 21708
2021-10-28 3 FORM 3 SUBMISSION 0000899243-21-041963 7494
2021-10-28 3 FORM 3 SUBMISSION 0000899243-21-041961 8641
2021-10-28 3 FORM 3 SUBMISSION 0000899243-21-041958 7407
2021-10-28 3 FORM 3 SUBMISSION 0000899243-21-041957 9880
2021-10-28 3 FORM 3 SUBMISSION 0000899243-21-041955 8657
2021-10-28 3 FORM 3 SUBMISSION 0000899243-21-041954 11704
2021-10-28 3 FORM 3 SUBMISSION 0000899243-21-041952 7404
2021-10-28 3 FORM 3 SUBMISSION 0000899243-21-041951 18086
2021-10-28 3 FORM 3 SUBMISSION 0000899243-21-041946 8764
2021-10-28 SEC STAFF LETTER filename1.pdf 9999999997-21-005591 274006
2021-10-28 CERT 8A_Cert_AURA.pdf 0001354457-21-001235 001-40971 211357516 34 217020
2021-10-26 8-A12B 8-A12B 0001193125-21-307948 001-40971 211348408 34 14350
2021-10-26 CORRESP filename1.htm 0001193125-21-307939 10828
2021-10-26 CORRESP filename1.htm 0001193125-21-307936 6968
2021-10-25 CORRESP filename1.htm 0001193125-21-305947 15285
2021-10-25 S-1/A S-1/A 0001193125-21-305934 333-260156 211342081 33 10508922
2021-10-13 UPLOAD filename1.pdf 0000000000-21-012395 43930
2021-10-08 CORRESP filename1.htm 0001193125-21-295546 22378
2021-10-08 S-1 S-1 0001193125-21-295543 333-260156 211315750 33 11125974
2021-09-27 UPLOAD filename1.pdf 0000000000-21-011723 46899
2021-09-21 SEC STAFF LETTER filename1.pdf 9999999997-21-004821 276018
2021-09-20 DRS/A filename1.htm 0000950123-21-012472 377-05331 211261867 33 10103718
2021-09-17 DRSLTR filename1.htm 0000950123-21-012473 36731
2021-09-10 UPLOAD filename1.pdf 0000000000-21-011050 55232
2021-08-10 DRS filename1.htm 0000950123-21-009996 377-05331 211157739 33 9316483
2021-04-06 D xslFormDX01/primary_doc.xml 06b 0001501796-21-000001 021-394732 21807414 33 9897
2020-07-09 D xslFormDX01/primary_doc.xml 06b 0001501796-20-000002 021-370627 201020963 33 12403
2019-04-12 D xslFormDX01/primary_doc.xml 06b 0001501796-19-000001 021-337166 19745452 33 13300
2018-12-13 D/A xslFormDX01/primary_doc.xml 06b 0001501796-18-000002 021-302255 181232895 33 12626
2018-01-03 D xslFormDX01/primary_doc.xml 06b 0001501796-18-000001 021-302255 18505017 33 12533
2017-11-02 D/A xslFormDX01/primary_doc.xml 06b 0001501796-17-000001 021-271656 171171342 33 13529
2016-09-30 D xslFormDX01/primary_doc.xml 06b 0001501796-16-000004 021-271656 161913001 33 14263
2015-03-05 D xslFormDX01/primary_doc.xml 06c 0001501796-15-000001 021-235305 15677372 33 12779
2014-08-14 D xslFormDX01/primary_doc.xml 06c 0001501796-14-000002 021-222909 141040240 33 10849
2014-01-08 D xslFormDX01/primary_doc.xml 06c 0001501796-14-000001 021-209519 14515661 33 10854
2012-12-26 D xslFormDX01/primary_doc.xml 06 0001501796-12-000001 021-188934 121284062 33 10061
2011-08-26 D xslFormDX01/primary_doc.xml 06 0001501796-11-000001 021-164993 111058071 33 10085
2010-09-21 D xslFormDX01/primary_doc.xml 06 0001501796-10-000001 021-148022 101082879 33 10522

Latest XBRL company facts

One latest value per concept from companyfacts (219 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 104.07M 2026-11-04 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
dei EntityPublicFloat Entity Public Float USD 321.00M 2025-06-30 2025 FY 10-K 2026-03-30 0001193125-26-130401
ffd NetFeeAmt NetFeeAmt USD 1,083.24 2026-09-01 S-8 2026-09-01 0001193125-26-378494
ffd TtlFeeAmt TtlFeeAmt USD 1,083.24 2026-09-01 S-8 2026-09-01 0001193125-26-378494
ffd TtlOfferingAmt TtlOfferingAmt USD 7.84M 2026-09-01 S-8 2026-09-01 0001193125-26-378494
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-09-01 S-8 2026-09-01 0001193125-26-378494
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-08-07 S-3 2026-08-11 0001193125-26-344699
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 1.72M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap AccruedEmployeeBenefitsCurrent Accrued Employee Benefits, Current USD 7.85M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 266,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 7.82M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -1.57M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 919.90M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap AdjustmentsToAdditionalPaidInCapitalOther Adjustments to Additional Paid in Capital, Other USD 27,000 2025-01-01 2025-03-31 2025 Q3 10-Q 2025-11-13 0001193125-25-278817
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 4.92M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 21.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 27.03M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap AreaOfRealEstateProperty Area of Real Estate Property sqft 4,516 2021-03-31 2022 FY 10-K 2023-03-15 0000950170-23-008166
us-gaap AssetImpairmentCharges Asset Impairment Charges USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap Assets Assets USD 321.62M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap AssetsCurrent Assets, Current USD 303.10M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 1.13M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 256.70M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value USD 30.10M 2024-09-30 2024 Q3 10-Q 2024-11-12 0000950170-24-125428
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 255.56M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 7,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-11 0001193125-26-343429
us-gaap Cash Cash USD 149.06M 2021-12-31 2021 FY 10-K 2022-03-23 0000950170-22-004425
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 41.67M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 144.20M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 42.44M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 42.44M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect USD -17.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -9.39M 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-24 0000950170-25-043943
us-gaap CashCollateralForBorrowedSecurities Cash Collateral for Borrowed Securities USD 20,000 2021-12-31 2021 FY 10-K 2022-03-23 0000950170-22-004425
us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights shares 11.17M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 11.17M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 500.00M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 103.95M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 103.95M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap CommonStockValue Common Stock, Value, Issued USD 1,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -112.86M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 137,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-27 0000950170-24-036814
us-gaap CurrentForeignTaxExpenseBenefit Current Foreign Tax Expense (Benefit) USD 30,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 108,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 78,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer USD 700,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months USD 400,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap DeferredCosts Deferred Costs, Noncurrent USD 1.58M 2021-09-30 2021 Q3 10-Q 2021-11-24 0000950170-21-004908
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 1.60M 2021-09-30 2021 Q3 10-Q 2021-11-24 0000950170-21-004908
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 8,000 2020-12-31 2021 FY 10-K 2022-03-23 0000950170-22-004425
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 150.55M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 24.44M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 84.24M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 993,000 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 31.98M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 3.01M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities USD 1.02M 2023-12-31 2023 FY 10-K 2024-03-27 0000950170-24-036814
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 145.73M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap DeferredTaxLiabilitiesLeasingArrangements Deferred Tax Liabilities, Leasing Arrangements USD 4.12M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 266,000 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap Depreciation Depreciation USD 785,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap DividendsCommonStockStock Dividends, Common Stock, Stock USD 0 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-23 0000950170-22-004425
us-gaap DividendsPreferredStock Dividends, Preferred Stock USD 10.94M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008166
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -1.22 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.44 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0000950170-22-009719
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -1.22 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0.001 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.331 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure -0.017 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure -0.036 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-24 0000950170-25-043943
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure 0.025 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD -247,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 27.60M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD -16,000 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-11 0000950170-22-016911
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 USD 0 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0000950170-22-009719
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 USD 0 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0000950170-22-009719
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 USD 0 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-11 0000950170-22-016911
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 USD 0 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0000950170-22-009719
us-gaap FinanceLeasePrincipalPayments Finance Lease, Principal Payments USD 15,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008166
us-gaap FinanceLeaseRightOfUseAssetAmortization Finance Lease, Right-of-Use Asset, Amortization USD 11,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008166
us-gaap FinanceLeaseWeightedAverageDiscountRatePercent Finance Lease, Weighted Average Discount Rate, Percent pure 0.079 2021-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008166
us-gaap GainLossOnDispositionOfAssets1 Gain (Loss) on Disposition of Assets USD 208,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-24 0000950170-25-043943
us-gaap GainLossOnInvestments Gain (Loss) on Investments USD -9,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008166
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-24 0000950170-25-043943
us-gaap GainLossOnTerminationOfLease Gain (Loss) on Termination of Lease USD -296,000 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-27 0000950170-24-036814
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 34.55M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -106.91M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -111.31M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD 828,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 100,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 77,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 35.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -22.28M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap IncomeTaxReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount USD 1.79M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 124,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 78,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD -2.73M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 173,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD 2.71M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -1.21M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap IncreaseDecreaseInOtherNoncurrentAssets Increase (Decrease) in Other Noncurrent Assets USD 696,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap IncreaseDecreaseInPrepaidExpensesOther Increase (Decrease) in Prepaid Expenses, Other USD 367,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap InterestIncomeExpenseAfterProvisionForLoanLoss Interest Income (Expense), after Provision for Loan Loss USD 6.51M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap InterestReceivable Interest Receivable USD 1.87M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap LeaseCost Lease, Cost USD 4.58M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 21.81M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 6.28M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 3.51M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 3.83M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 3.83M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 3.71M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 3.61M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 866,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 5.64M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap Liabilities Liabilities USD 34.19M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 321.62M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap LiabilitiesCurrent Liabilities, Current USD 21.34M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap MarketableSecurities Marketable Securities USD 255.56M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss USD 1.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 242.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -171.02M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -88.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -111.39M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 6.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OperatingCostsAndExpenses Operating Costs and Expenses USD 118.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -118.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OperatingLeaseCost Operating Lease, Cost USD 2.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 4,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-23 0000950170-22-004425
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 16.17M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 3.32M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 12.85M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OperatingLeasePayments Operating Lease, Payments USD 2.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 14.56M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.107 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 146,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OtherAssetsCurrent Other Assets, Current USD 851,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 1.17M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -1.22M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax USD -247,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD -1.47M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OtherExpenses Other Expenses USD 11,000 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-11 0000950170-22-016911
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD 9,000 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0000950170-22-009719
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 172,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap OtherOperatingActivitiesCashFlowStatement Other Operating Activities, Cash Flow Statement USD 27,000 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-15 0000950170-25-071907
us-gaap PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock USD 39.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap PaymentsForRestructuring Payments for Restructuring USD 516,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 1.42M 2021-01-01 2021-09-30 2022 Q3 10-Q 2022-11-10 0000950170-22-024150
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 269.32M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 203,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap PreferredStockConvertibleConversionRatio PreferredStockConvertibleConversionRatio pure 1 2021-09-30 2021 Q3 10-Q 2021-11-24 0000950170-21-004908
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 5.87M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap PrepaidInsurance Prepaid Insurance USD 435,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-24 0000950170-25-043943
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 259.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ProceedsFromIssuanceOfWarrants Proceeds from Issuance of Warrants USD 21.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ProceedsFromIssuanceOrSaleOfEquity Proceeds from Issuance or Sale of Equity USD 350.00M 2024-03-27 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ProceedsFromPaymentsForOtherFinancingActivities Proceeds from (Payments for) Other Financing Activities USD -15,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008166
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 98.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Proceeds from Sale of Debt Securities, Available-for-sale USD 68.95M 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-08 0000950170-24-093308
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 174,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 257,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 155,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -111.39M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 9.84M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 2.02M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008166
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 83.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap RestrictedCashAndCashEquivalentsAtCarryingValue Restricted Cash and Cash Equivalents, Current USD 0 2024-12-31 2024 FY 10-K 2025-03-24 0000950170-25-043943
us-gaap RestrictedCashAndCashEquivalentsNoncurrent Restricted Cash and Cash Equivalents, Noncurrent USD 768,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap RestructuringCharges Restructuring Charges USD 4.50M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap RestructuringReserve Restructuring Reserve USD 2.70M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -591.81M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 21.21M 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-27 0000950170-24-036814
us-gaap SecurityDeposit Security Deposit USD 800,000 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 21.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.906 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.043 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 30,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 5.35 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value USD 8.30M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 9.57 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-15 0000950170-25-071907
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 7.64 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-15 0000950170-25-071907
us-gaap SharesOutstanding Shares, Outstanding shares 115,054 2022-09-30 2022 Q3 10-Q 2022-11-10 0000950170-22-024150
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-24 0000950170-25-043943
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 287.43M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.073 2021-10-22 2022 FY 10-K 2023-03-15 0000950170-23-008166
us-gaap StockholdersEquityOther Stockholders' Equity, Other USD 27,000 2025-01-01 2025-03-31 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap StockIssued1 Stock Issued USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Stock Issued During Period, Shares, Employee Stock Purchase Plans shares 6,635 2023-01-01 2023-03-31 2024 Q3 10-Q 2024-11-12 0000950170-24-125428
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 215.30M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008166
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 136,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 38,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap StockRepurchasedDuringPeriodValue Stock Repurchased During Period, Value USD 39.09M 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap TemporaryEquityAccretionToRedemptionValueAdjustment Temporary Equity, Accretion to Redemption Value, Adjustment USD 10.94M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-23 0000950170-22-004425
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 128.08M 2020-12-31 2021 FY 10-K 2022-03-23 0000950170-22-004425
us-gaap TemporaryEquityParOrStatedValuePerShare Temporary Equity, Par or Stated Value Per Share USD/shares 0 2021-11-02 2023 Q1 10-Q 2023-05-11 0000950170-23-021302
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 10.00M 2021-11-02 2023 Q1 10-Q 2023-05-11 0000950170-23-021302
us-gaap TreasuryStockCommonShares Treasury Stock, Common, Shares shares 6.92M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap TreasuryStockCommonValue Treasury Stock, Common, Value USD 39.09M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 0 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued Unrecognized Tax Benefits, Interest on Income Taxes Accrued USD 0 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate USD 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 39.90M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130401
us-gaap VariableLeaseCost Variable Lease, Cost USD 1.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 91.29M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 29.21M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0000950170-22-009719
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 91.29M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452636

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →